NEWS
WHO Adds GLP-1 Drugs to Essential Medicines: What It Means for Access
WHO recognition can accelerate equitable access to GLP-1s for diabetes. Policy, pricing, and system-level implications.
Dr. Sarah Chen
November 3, 2025
5 min read
WHO Adds GLP-1 Drugs to Essential Medicines: What It Means for Access
The World Health Organization’s inclusion of GLP-1 drugs in the Model List of Essential Medicines signals their clinical importance in diabetes care and could catalyze broader, more equitable access globally.
Expected Impacts
- Procurement leverage: Facilitates national tenders and negotiated pricing.
- Guideline alignment: Encourages standardized use in appropriate populations.
- Health equity: Improves access in lower-income settings over time.
Considerations for Health Systems
- Ensure supply chain capacity and cold-chain integrity.
- Train clinicians on dose escalation and side-effect management.
- Pair access expansion with nutrition and prevention programs.
- Procurement leverage: Facilitates national tenders and negotiated pricing.
- Guideline alignment: Encourages standardized use in appropriate populations.
- Health equity: Improves access in lower-income settings over time.
Considerations for Health Systems
- Ensure supply chain capacity and cold-chain integrity.
- Train clinicians on dose escalation and side-effect management.
- Pair access expansion with nutrition and prevention programs.
About Dr. Sarah Chen
Endocrinologist and peptide research specialist with 15+ years of experience in metabolic medicine.
EndocrinologyGlobal HealthDiabetes Care
Related Articles
NEWS
Navigating the GLP-1 Gray Market: Access, Affordability, and Safety in 2025
High demand and limited coverage have pushed some to gray-market GLP-1s. Learn the risks, legal context, safer access routes, and cost strategies.
Dr. Sarah Chen
Nov 3, 2025
8 min read
GLP-1 medicationsgray marketOzempic+3 more
CLINICAL TRIALS
How GLP-1 Medications Are Reshaping Consumer Behavior and Markets
From grocery baskets to wellness spend, GLP-1s are changing consumer habits. What brands and patients should know.
Dr. James Wilson
Nov 3, 2025
7 min read
GLP-1 medicationsconsumer behaviormarket trends+2 more
WEIGHT LOSS
GLP-1 Receptor Agonists and Alcohol: What Early Studies Show in Obesity
Preliminary data suggest GLP-1 RAs may alter alcohol’s physiological and perceptual effects in people with obesity. What to know and discuss with your clinician.
Dr. Sarah Chen
Nov 3, 2025
6 min read
GLP-1 receptor agonistsalcohol consumptionobesity+1 more